Prelude Therapeutics
Manufacturing · Delaware, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
175 Innovation Blvd, Wilmington, Delawar...Phone Number
(302) 467-1280Website
www.preludetx.comRevenue
$22.4 MillionStock Symbol
PRLDIndustry
About Prelude Therapeutics
Prelude Therapeutics Incorporated is a clinical-stage precision oncology company headquartered in Wilmington, Delaware, dedicated to developing innovative medicines for cancer patients with high unmet needs. Its pipeline features highly selective KAT6A degraders and mutant-selective JAK2V617F JH2 inhibitors targeting clinically validated cancer pathways, alongside next-generation degrader antibody conjugates leveraging its targeted protein degradation expertise. Founded in 2016, Prelude Therapeutics trades publicly on the NASDAQ under the ticker PRLD.Explore more
Prelude Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Prelude Therapeutics
Compare insights from companies similar to Prelude Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Public
$29.8M
1997
LW
Lauren WittberAssociate Director, Accounting, SEC Reporting & Financial Analysis
Prelude Therapeutics Tech Stack
A closer look at the technologies used by Prelude Therapeutics
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Prelude Therapeutics
Sign Up For FreeTo access detailed company insights
Prelude Therapeutics Incorporated is a clinical-stage precision oncology company headquartered in Wilmington, Delaware, dedicated to developing innovative medicines for cancer patients with high unmet needs. Its pipeline features highly selective KAT6A degraders and mutant-selective JAK2V617F JH2 inhibitors targeting clinically validated cancer pat... Read More
